Pro-inflammatory cytokine and matrix metalloproteinase pathways

The pro-inflammatory cytokine and matrix metalloproteinase (MMP) pathways represent a complex signaling network where cytokines like TNF-alpha, IL-1 beta, and IL-6 trigger the production and activation of MMPs (PMID: 11807199). MMPs are zinc-dependent endopeptidases responsible for degrading extracellular matrix (ECM) components, a process essential for normal tissue remodeling but pathological when overactivated (PMID: 12478482). In chronic inflammatory diseases such as rheumatoid arthritis and osteoarthritis, this axis drives joint destruction and cartilage loss through the degradation of collagen and proteoglycans. In oncology, the pathway facilitates tumor invasion and metastasis by breaking down basement membranes and promoting angiogenesis (PMID: 10472028). Therapeutic strategies include neutralizing cytokines to prevent MMP induction or using small molecules like doxycycline to inhibit MMP catalytic activity directly (FDA: Periostat). However, broad MMP inhibition has historically faced challenges due to lack of specificity and side effects like musculoskeletal syndrome, while cytokine inhibition carries risks of immunosuppression and infection. This pathway is also critical in cardiovascular diseases, where MMPs contribute to atherosclerotic plaque instability and rupture (PMID: 15131214).

Other names

Cytokine-MMP axisInflammatory-proteolytic cascadePro-inflammatory signaling and ECM degradation pathway

Inhibition of pro-inflammatory cytokine signaling to downregulate MMP expression, or direct inhibition of MMP enzymatic activity to prevent extracellular matrix degradation.